GSK's (GSK) "Hold" Rating Reiterated at Deutsche Bank Aktiengesellschaft

Key Points

• Deutsche Bank reiterated a “Hold” rating on GSK and maintained a GBX 2,000 price target, implying approximately 10.77% upside. MarketBeat’s consensus rating is also “Hold,” with an average target of GBX 2,064.38.
• GSK shares fell to GBX 1,805.50 during Thursday trading, while the company reported quarterly EPS of GBX 54.60, revenue of approximately £888.7 billion, a 14.52% net margin and a 28.35% return on equity.
• Analyst views remain mixed: Jefferies maintained a “Buy” rating with a GBX 2,500 target, while Berenberg and RBC kept neutral ratings. Insiders also purchased shares recently, including 1,500 shares bought by Jonathan Symonds.

GSK (LON:GSK - Get Free Report)'s stock had its "hold" rating reissued by analysts at Deutsche Bank Aktiengesellschaft in a note issued to investors on Thursday, Digital Look reports. They presently have a GBX 2,000 target price on the stock. Deutsche Bank Aktiengesellschaft's target price suggests a potential upside of 10.77% from the stock's current price.

A number of other brokerages also recently issued reports on GSK. Berenberg Bank increased their price objective on shares of GSK from GBX 2,000 to GBX 2,200 and gave the stock a "hold" rating in a research note on Tuesday, September 15th. Royal Bank Of Canada restated a "sector perform" rating and set a GBX 1,975 price objective on shares of GSK in a research report on Tuesday, September 8th. Finally, Jefferies Financial Group reiterated a "buy" rating and issued a GBX 2,500 price target on shares of GSK in a research note on Tuesday, October 20th. Two analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of GBX 2,064.38.

GSK Stock Performance

Shares of LON GSK traded down GBX 26 during mid-day trading on Thursday, reaching GBX 1,805.50. 80,525,984 shares of the company were exchanged, compared to its average volume of 12,671,819. The stock has a market capitalization of £72.35 billion, a P/E ratio of 15.33, a P/E/G ratio of 1.24 and a beta of 0.29. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 103.36. GSK has a twelve month low of GBX 1,690 and a twelve month high of GBX 2,282. The company's 50-day simple moving average is GBX 1,849.02 and its 200-day simple moving average is GBX 1,949.41.

GSK (LON:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The company reported GBX 54.60 EPS for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. The business had revenue of GBX 888.70 billion for the quarter. As a group, research analysts predict that GSK will post 175.98 earnings per share for the current year.

Insider Activity

In other GSK news, insider Jonathan Symonds purchased 1,500 shares of GSK stock in a transaction that occurred on Friday, September 18th. The stock was acquired at an average price of GBX 1,881 per share, with a total value of £28,215. Also, insider Anne Beal purchased 637 shares of the stock in a transaction that occurred on Friday, September 18th. The stock was bought at an average cost of GBX 4,985 per share, with a total value of £31,754.45. Over the last 90 days, insiders bought 2,151 shares of company stock valued at $6,021,921. 0.20% of the stock is currently owned by company insiders.

GSK News Summary

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK reported third-quarter revenue of approximately £8.9 billion, while core operating profit and core earnings per share modestly exceeded analyst expectations. Growth in specialty medicines and newer products helped drive the performance. GSK tops third-quarter estimates as new medicines drive growth
• Positive Sentiment: The company said its strategy is gaining traction and plans to nearly double the number of cancer medicines in clinical trials next year, supporting its longer-term pipeline and growth prospects. GSK to nearly double cancer medicines in clinical trials next year
• Neutral Sentiment: GSK reaffirmed its 2026 outlook for 3% to 5% turnover growth and 7% to 9% growth in core operating profit and core EPS. While the unchanged guidance provides stability, investors had been looking for a stronger outlook following the earnings beat. GSK keeps guidance as specialty drugs power sales
• Negative Sentiment: Vaccines were the main disappointment: overall vaccine revenue fell 2%, with Shingrix down 5% and Arexvy down 24%. The weakness overshadowed growth in specialty medicines and raised concerns about demand for key brands. GSK slides as weak vaccine sales overshadow quarterly beat
• Negative Sentiment: A £328 million restructuring charge connected with GSK’s Accelerate Growth program contributed to a 16% decline in reported operating profit and a 21% fall in total EPS. Higher financing costs also weighed on reported results, making the headline profit figures less attractive despite the underlying beat. GSK Q3 2026 revenue blowout masked by restructuring charges
• Negative Sentiment: GSK’s weakness also pressured the broader FTSE 100, indicating that the earnings reaction was a notable drag on the UK market rather than an isolated investor concern. UK’s FTSE 100 muted as GSK losses temper bank gains

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.